Bringing the Oncology Community Together

Advances in Prostate Cancer Treatment Highlighted at ASCO

Published Online: Monday, August 19, 2013
Dr. Bertrand Tombal

Bertrand Tombal, MD, PhD

Efficacy and safety data for enzalutamide (Xtandi) monotherapy; a pain analysis from the phase III ALSYMPCA study of radium-223 (Xofigo); long-term safety and efficacy results from the COU-AA-302 study of abiraterone acetate (Zytiga); and a molecular characterization of patients more likely to benefit from abiraterone acetate are among the many presentations at the 2013 ASCO Annual Meeting that provided clinically useful information for the care of patients with prostate cancer.

Enzalutamide Monotherapy as Alternative to Standard Hormone Therapy

In a phase II study in patients with hormone-naïve prostate cancer, the oral androgen receptor (AR) inhibitor enzalutamide achieved a “high response rate and marked PSA decline,” with efficacy similar to castration but without the side effects of androgen- deprivation therapy.1 During the 6-month, single- arm trial, bone mineral density remained stable and metabolic variables, such as fat body mass, lipid profiles, and glycemic profiles did not show substantial changes.

The researchers assessed enzalutamide monotherapy at the approved dose of 160 mg per day for 25 weeks in patients with hormone-naïve prostate cancer and noncastrate testosterone ≥230 ng/dL (N = 67). The primary endpoint was PSA response, defined as ≥80% decline at the study’s end.

“We know that a lot of patients will need androgen- deprivation therapy,” said principal investigator Bertrand Tombal, MD, PhD, professor and chairman, Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, in a presentation at ASCO 2013. “In Europe, we have been using androgen monotherapy…and these drugs have the ability to control the cancer without requiring androgen-deprivation therapy.” The goal is to develop an alternative to standard hormone therapy.

“We took a really conservative approach in these patients…showing a PSA drop of more than 80%, to be sure, at least, that if it didn’t reach that endpoint, we would know that we couldn’t go further. In fact, it did much better than that, depressing PSA very, very profoundly. “Antiandrogen monotherapy is not an unfinished business,” Tombal added. But there are promises for patients in a few years for a drug that could do the same as androgen-deprivation therapy without the side effects.

Asked about a key message for clinicians today, Tombal said, “Look at these drugs and try to think outside the box of standard hormonal therapy.”

Radium-223 Reduces Pain and Opioid Use

The FDA approved radium-223 dichloride (radium- 223; Xofigo) in May for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The decision was based on results from the phase III ALSYMPCA study. A post hoc pain analysis of ALSYMPCA reported at ASCO 2013 by Sten Nilsson, MD, PhD, from the University of Oslo, Norway, found that in addition to prolonging survival, radium-223 reduced pain and opioid use in patients with CRPC and bone metastases.2

Radium-223 is an alpha-particle-emitting radiotherapeutic drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover, such as bone metastases. In ALSYMPCA, patients with CRPC with bone metastases were randomized 2:1 to six injections of radium-223 (n = 614) or placebo (n = 307).

The Cox proportional hazards model was used by Nilsson et al for an analysis of time to initial opioid use and time to external-beam radiation therapy. Pain-related quality of life (QoL) was analyzed using the Functional Assessment of Cancer Therapy-Prostate subscale, using ANCOVA.

At baseline, approximately 55% of ALSYMPCA patients had moderate-to-severe pain and opioid use, based on the World Health Organization ladder for cancer pain.

The median time to opioid use was significantly longer in the radium-223 group, with a risk reduction of 38% versus placebo (hazard ratio = 0.621; 95% CI, 0.456-0.846). Fewer patients who received radium-223 required opioids for pain relief than placebo-treated patients (36% vs 50%, respectively). And at week 16, the QoL pain score reflected significant reductions in pain among the radium-223 group (P = .001).

Additional COU-AA-302 Abiraterone Acetate Data

The international COU-AA-302 trial assessed the clinical benefit of abiraterone acetate (AA) plus prednisone versus prednisone alone in 1088 chemotherapy- naïve mildly symptomatic or asymptomatic patients with progressive metastatic CRPC (mCRPC). The study was the basis for the FDA’s decision in December to expand the indication of AA to the prechemotherapy setting for mCRPC.

Page: 12Next Page (2) >>
Related Articles
Early Detection of Metastatic Prostate Cancer
In this segment, panelists discuss advanced imaging techniques that can be used to detect metastases earlier for patients with castration-resistant prostate cancer.
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD
An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.